These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27683469)

  • 1. KLK-targeted Therapies for Prostate Cancer.
    Hannu K; Johanna M; Ulf-Håkan S
    EJIFCC; 2014 Sep; 25(2):207-18. PubMed ID: 27683469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
    Avgeris M; Scorilas A
    Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application.
    Fuhrman-Luck RA; Loessner D; Clements JA
    EJIFCC; 2014 Oct; 25(3):269-81. PubMed ID: 27683474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of peptides specifically modulating the activity of KLK2 and KLK3.
    Koistinen H; Närvänen A; Pakkala M; Hekim C; Mattsson JM; Zhu L; Laakkonen P; Stenman UH
    Biol Chem; 2008 Jun; 389(6):633-42. PubMed ID: 18627344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kallikreins as biomarkers for prostate cancer.
    Hong SK
    Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation and activity of glycosylated KLKs 3, 4 and 11.
    Guo S; Briza P; Magdolen V; Brandstetter H; Goettig P
    Biol Chem; 2018 Sep; 399(9):1009-1022. PubMed ID: 29975661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
    Pampalakis G; Sotiropoulou G
    Biochim Biophys Acta; 2007 Sep; 1776(1):22-31. PubMed ID: 17629406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin.
    Emami N; Diamandis EP
    J Biol Chem; 2008 Feb; 283(6):3031-3041. PubMed ID: 18056261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.
    Cereda V; Formica V; Menghi A; Pellicori S; Roselli M
    Expert Opin Investig Drugs; 2015; 24(7):929-47. PubMed ID: 25858813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting kallikrein-related peptidases in prostate cancer.
    Mavridis K; Avgeris M; Scorilas A
    Expert Opin Ther Targets; 2014 Apr; 18(4):365-83. PubMed ID: 24571737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KLKs and their hormone-like signaling actions: a new life for the PSA-KLK family.
    Hollenberg MD
    Biol Chem; 2014 Sep; 395(9):915-29. PubMed ID: 25153380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.
    Kryza T; Silva ML; Loessner D; Heuzé-Vourc'h N; Clements JA
    Biochimie; 2016 Mar; 122():283-99. PubMed ID: 26343558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer.
    Lovell S; Zhang L; Kryza T; Neodo A; Bock N; De Vita E; Williams ED; Engelsberger E; Xu C; Bakker AT; Maneiro M; Tanaka RJ; Bevan CL; Clements JA; Tate EW
    J Am Chem Soc; 2021 Jun; 143(23):8911-8924. PubMed ID: 34085829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolutionary history of tissue kallikreins.
    Pavlopoulou A; Pampalakis G; Michalopoulos I; Sotiropoulou G
    PLoS One; 2010 Nov; 5(11):e13781. PubMed ID: 21072173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers.
    Emami N; Diamandis EP
    Clin Chem; 2008 Oct; 54(10):1600-7. PubMed ID: 18687738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
    Figueroa CD; Molina L; Bhoola KD; Ehrenfeld P
    Biol Chem; 2018 Sep; 399(9):937-957. PubMed ID: 29885274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches.
    Veveris-Lowe TL; Kruger SJ; Walsh T; Gardiner RA; Clements JA
    Semin Thromb Hemost; 2007 Feb; 33(1):87-99. PubMed ID: 17253195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer.
    Matin F; Jeet V; Srinivasan S; Cristino AS; Panchadsaram J; Clements JA; Batra J;
    Clin Chem; 2019 Jun; 65(6):771-780. PubMed ID: 31018918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new human kallikrein gene family: implications in carcinogenesis.
    Diamandis EP; Yousef GM; Luo LY; Magklara A; Obiezu CV
    Trends Endocrinol Metab; 2000 Mar; 11(2):54-60. PubMed ID: 10675891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.
    Williams SA; Xu Y; De Marzo AM; Isaacs JT; Denmeade SR
    Prostate; 2010 May; 70(7):788-96. PubMed ID: 20058238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.